Biologic therapies push pharma to rethink inactive ingredients As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access. Written byLisa Stehno-Bittel

Biologic therapies push pharma to rethink inactive ingredients As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access. Written byLisa Stehno-Bittel https://www.drugdiscoverynews.com/biologic-therapies-push-pharma-to-rethink-inactive-ingredients-16887?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-89N4pgchHPkdaBRoggYvr9bo878sEPPOn6mBQiBp631YhwTWxzcDPu1IZWPfj_tKpo9--AG861gEfnhXOkpDcP_U41LA&_hsmi=427377385&utm_content=427377385&utm_source=hs_email The pharmaceutical industry has undergone a seismic shift toward biologics, enabling entirely new classes of active ingredients. But the discovery and use of inactive ingredients, or excipients, has failed to keep pace, leaving drug developers trying to optimize next-generation therapies with toolsets designed for a different purpose. Excipient innovation is long overdue, but new options are finally available to developers, helping biologics reach their potential for the first time.